JP3885204B2 - External agent for promoting cell activity - Google Patents
External agent for promoting cell activity Download PDFInfo
- Publication number
- JP3885204B2 JP3885204B2 JP2002113217A JP2002113217A JP3885204B2 JP 3885204 B2 JP3885204 B2 JP 3885204B2 JP 2002113217 A JP2002113217 A JP 2002113217A JP 2002113217 A JP2002113217 A JP 2002113217A JP 3885204 B2 JP3885204 B2 JP 3885204B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- cells
- cell
- cell activity
- promoting cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、細胞活性促進外用剤に係り、主に花粉症や口内炎などの諸疾患に優れた改善効果を有すると共に、細胞に対しての電解質バランス、浸透圧バランスを応用して細胞を活性化し、膚細胞の細胞機能低下による諸疾患を改善する細胞活性促進外用剤に関するものである。
【0002】
【従来の技術】
従来、塩化ナトリウム等の無機塩や、ブドウ糖等の天然糖、或いは血漿などは、夫々化粧品や医薬外用剤の配合剤として広く使用されている。例えば、塩化ナトリウム等を含んだ肌を和らげるクリームに関するものが、U.S.P.3574854号公報に記載され、一方、ミネラル塩類を含んだ皮膚を衛生的にする出願は、西独国特許出願公開第3327840号明細書に見られる。更に、グルコース等を混合した肌を滑らかにする糖の成分に関する出願として、U.S.P.3859436号公報に記載され、また、シェービング用デキストラン水溶液に関する出願は、U.S.P.3777597号公報に記載されている。
【0003】
ところが、これら従来の外用剤では、皮膚殺菌及び皮膚の保護の目的が達せられても、皮膚の毛細血管の循環及び機能低下による皮膚疾患、すなわち色素沈着症、水虫、インキン、タムシ、ワキガ、脱毛症、フケ、かゆみ等の皮膚細胞分裂機能低下による諸疾患を改善することは困難であった。
【0004】
そこで、当発明者は、皮膚細胞を活性化し、皮膚細胞の細胞機能低下による諸疾患を改善するものとして、皮膚細胞間質液と同様な環境を皮膚表面に作り出し、電解質バランス、浸透圧バランスを応用することで、皮膚の表面からも障害細胞の正常化を促進することが可能になった水性皮膚及び毛髪化粧料を発明している(特許第1597430号)。
【0005】
そして、この水性皮膚及び毛髪化粧料にあっては、シミ、赤ら顔の場合は皮下細胞を刺激、分裂させ、治癒に導びき、また、頭皮、ワキガ等に対しては浸透圧作用により毛母細胞を刺激し、発毛及び脱臭作用を促進させる効果が見られた。すなわち、この水性皮膚及び毛髪化粧料では、脱毛症に対する治癒率が83%、色素沈着症に対する治癒率が95%、赤ら顔の治療率が53%といった効能結果が得られている。
【0006】
ところが、これらの効能は、主に皮膚や毛髪に対して顕著な効果が認められたものであり、当発明者は、皮膚細胞等の活性化の如く、副作用なしで粘膜細胞をも活性化させ得るなら、口腔の粘膜疾患による口内炎や、鼻粘膜の障害による花粉症などの疾患にもその効能が及ぶ可能性に着眼した。
【0007】
そこで当発明者は、更に、口腔や鼻粘膜用の外用剤として使用しても副作用の虞が全く無く、例えば、口内炎や花粉症などといった、より広範囲な細胞レベルにおける諸疾患にも適用することが可能な細胞活性促進外用剤を発明している(特許第2681527号)。この細胞活性促進外用剤は、デキストラン等の多糖類やブドウ糖、ムタン、レンチナンなどを添加したものである。この細胞活性促進外用剤では、口内炎に対する治癒率が100%、花粉症に対する治癒率が100%といった優れた結果が得られている。
【0008】
【発明が解決しようとする課題】
ところが、先の細胞活性促進外用剤において示された花粉症に対する治癒率は、当時、対象人数を40人とした場合に示されたものであり、その後、花粉症の患者が急増するにつれて、花粉症の治癒率が次第に低下する傾向にあった。すなわち、前回(平成2年)の効能試験において、花粉症で100%を示していた有効率は、その後、十数年を経過した今日、発症率の爆発的増加に反比例するように、有効率が急激に下降していることが分かった。そもそも、花粉症が発症する原因は未だ明らかになっていないが、個人的な要因が口腔や鼻粘膜等の細胞レベルに何等かの影響を与えて発症を誘発すると考えられている。したがって、口腔や鼻粘膜等の免疫力や治癒力を高め、細胞組織を健康な状態に保つことで、個々の要因による悪影響を防止することが可能になり、急増する花粉症の発症を抑止すると共に、治癒効果も生じると考えられる。
【0009】
そこで本発明は、先に発明した細胞活性促進外用剤に更に改良を加えることで、口腔や鼻粘膜等の細胞組織の免疫力や治癒力を高め、しかも副作用の虞が全く無く、花粉症や口内炎は勿論、皮膚や頭皮等の広範囲な細胞レベルにおける諸疾患にも適用することが可能な細胞活性促進外用剤の提供を目的とする。
【0010】
【課題を解決するための手段】
上述の目的を達成すべく本発明の第1の手段は、多糖類を溶解した水溶液中に、全体の重量比で、デキストラン18%、ブドウ糖10%、サイクロデキストリン2%、トレハロース3%、プルラン7%、レンチナン7%、ラミナラン2%、クレスチン1%、ペクチン3%、キシログルカン1%、塩化ナトリウム0.9%、塩化カルシウム0.3%、塩化カリウム0.3%、精製水44.5%の各成分を全て添加したことにある。
【0011】
人間の皮膚における病変である炎症、色素沈着、脱毛症等の各種症状の原因は、紫外線、化学物質等の種々の因子が関連したものとなっており、その細胞レベルでの変化が限られているその根本は、細胞内小器官の一つであるミトコンドリアの膜や細胞膜の障害といえるものである。つまり、ミトコンドリアの膜の障害によって細胞内呼吸の阻害が生じ、これによって、細胞の活動源たるATP(アデノシン3リン酸)の産生が低下する。このようなATPの不足によって細胞膜の能動輸送の機能が低下し、細胞と間質液との間において物質の輸送能力の低下が起る。すると、細胞内におけるグルコース等の栄奏物質の不足を生じさせ、ひいてはATPの酸性の低下につながるといった悪循環をなすものである。
【0012】
以上のような細胞レベルでの変化を生じさせる原因は多様なものがあり、特に、口腔や鼻粘膜等の細胞においては、浸透圧作用で細胞問質液を引き上げることで、疾患部分の細胞を活性化することができる。更に、キシログルカンと、ラミラナンと、クレスチンとを添加することにより、口腔や鼻粘膜等の細胞組織の免疫力や治癒力を高めることが可能になると考えられる。
【0013】
【発明の実施の形態】
本発明の基本的な配合は、多糖類を溶解した水溶液中に、キシログルカン、ラミラナン、クレスチンの各成分を添加するものである。
【0014】
キシログルカンは、伸長・肥大している植物細胞の壁(一次壁)に普遍的に存在する構成糖鎖である。植物種特異性は、キシロース残基にガラクトースまたはフコシル−ガラクトースが結合することによって生じる。このガラクトース残基及びフコース残基にはそれぞれレクチンが結合できるが、これら分岐糖鎖の機能は分かっていない。植物細胞の成長は、細胞の持っている浸透圧に由来する吸水現象によって生じ、吸水力は、細胞壁のゆるみによる壁圧の減少によって生じる。この細胞壁のゆるみは、未だ解明されていないが、細胞伸長は常にキシログルカンの分解と可溶化を伴って生じており、細胞の生理活性をつかさどる多糖類のひとつとして注目されている。
【0015】
ラミラナンは、炭水化物の一でβグルカンのラミラナンとして分類される。椎茸をはじめとした茸類や昆布などの海草類に含まれるもので、免疫力を高める効果がある。単独では吸収され難く、たんぱく質と一緒に摂取するとよいことが知られている。
【0016】
クレスチンは、ヒト癌細胞のHLAクラスI抗原の発現を増強する免疫治療医薬品として使用されるもので、かわらたけ菌糸体より抽出される。このクレスチンは、胃癌、結腸・直腸癌、小細胞肺癌等の腫瘍性疾患に免疫治療作用が認められている。
【0017】
発明者は、数多くの多糖類の中から、外用剤に適した成分を研究した結果、これらのキシログルカン、ラミラナン、クレスチンを組合せることで、口腔や鼻粘膜等の細胞組織の免疫力や治癒力を高める外用剤を調製したものである。
【0018】
これらの多糖類を溶解した水溶液中には、予め、全体の重量比で、ペクチン、デキストラン、ブドウ糖、レンチナン、トレハロースの各成分を含有せしめてある。
【0019】
ペクチンは、植物の細胞壁の構成成分としてセルロース等、他の成分と結合することで植物細胞をつなぎ合わせる働きをしている。ゲル化作用を持つ成分であり、本発明外用剤の添加剤として好適である。
【0020】
また、多糖類を溶解した水溶液中に、塩化ナトリウムと、塩化カルシウムと、塩化カリウムとを添加している。塩化ナトリウムの配合量は、皮膚に対する浸透圧バランス、電解質バランスの有効性、すなわち、皮膚細胞を活性化できるよう、全体の重量比で0.9%とし、同様に、塩化カルシウムと、塩化カリウムにおいても0.3%の各成分を水相成分に溶解する。
【0021】
【実施例】
次に、処方例及び薬理試験例を挙げて本発明の外用剤を具体的に説明する。
【0022】
−処方例−
デキストラン 18
ブドウ糖 10
サイクロデキストリン 2
トレハロース 3
プルラン 7
レンチナン 7
ラミナラン 2
クレスチン 1
ペクチン 3
キシログルカン 1
塩化ナトリウム 0.9
塩化カルシウム 0.3
塩化カリウム 0.3
精製水 44.5
計 重量比(%) 100
【0023】
水相成分(精製水)は、純水のみで製造するノンオイルのもので、化粧品等、通常の外用剤の製造時に使用されている水溶性石油系の界面活性剤等は一切含有しない。そして、これらの各成分と水相成分との混合に際しては、各成分の溶解を完全にするために、50〜100℃の温度で実施する。
【0024】
次に、処方例1の効果を表1に示す。
【0025】
【表1】
【0026】
表1は、処方例1の薬理試験による結果を示すものである。このときの有効性とは、本発明外用剤の使用により、変化なしを0ポイント、治癒に向う変化があったものを1ポイント、効果が確認されたものを2ポイントとした各人の合計点を出し、次の式で算出したものである。尚、今回の試験は、特に花粉症の治癒効果を確認するために、疾患者100人を対象として有効率を算出した。
【0027】
【数1】
【0028】
この結果、100人の花粉症を対象にしても98%の有効率が得られた。前回(平成2年)の試験において、花粉症で100%を示していた有効率は、その後、十数年を経過した今日、発症率の爆発的増加に反比例するように、有効率が急激に下降していたが、本発明によって98%の有効率を維持できるようになっていることは特筆すべき効果であるといえる。また、600症例中、ただの一例も副作用が認められず、しかも、男性型脱毛症やニキビ、水虫、脂漏性皮膚炎など、治癒改善が困難な疾患に対しても極めて有効である。
【0029】
【発明の効果】
本発明によると、全体の重量比で、デキストラン18%、ブドウ糖10%、サイクロデキストリン2%、トレハロース3%、プルラン7%、レンチナン7%、ラミナラン2%、クレスチン1%、ペクチン3%、キシログルカン1%、塩化ナトリウム0.9%、塩化カルシウム0.3%、塩化カリウム0.3%、精製水44.5%の各成分を、水相成分に添加したことにより、口腔や鼻粘膜等の細胞組織の免疫力や治癒力を高めることが可能になり、花粉症などの個人的要因が作用する疾患でも有効な治癒効果が得られる。
【0030】
また、細胞組織の免疫力や治癒力を高めながら皮膚細胞間質液と同様な環境を作り出すことができるので、ミトコンドリアの膜の障害によって生じる、細胞内呼吸の阻害や、細胞の活動源たるATP(アデノシン3リン酸)の産生の低下を防止することができ、電解質バランス、浸透圧バランスを保ち、皮膚細胞や粘膜細胞の表層からも障害細胞の正常化を促進することが可能になり、男性型脱毛症やニキビ、水虫、脂漏性皮膚炎など、治癒改善が困難な疾患に対しても極めて有効であり、本発明の意義は極めて大きく、人類に大きく貢献するものである。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an agent for promoting cell activity, mainly having an improvement effect on various diseases such as hay fever and stomatitis, and activating cells by applying electrolyte balance and osmotic pressure balance to the cells. The present invention relates to an agent for promoting cell activity that improves various diseases caused by a decrease in skin cell function.
[0002]
[Prior art]
Conventionally, inorganic salts such as sodium chloride, natural sugars such as glucose, or plasma have been widely used as a formulation for cosmetics and pharmaceutical external preparations. For example, a cream relating to a soothing skin containing sodium chloride or the like is described in USP3574854, while an application for sanitizing skin containing mineral salts is disclosed in West German Patent Application No. 3327840. It can be seen. Further, an application relating to a sugar component that smoothes skin mixed with glucose or the like is described in USP3859436, and an application relating to a dextran aqueous solution for shaving is described in USP3777597.
[0003]
However, in these conventional external preparations, even if the purpose of skin sterilization and protection of the skin is achieved, skin diseases caused by the circulatory and functional deterioration of the skin capillaries, i.e., pigmentation, athlete's foot, insect, worm, hair loss, hair loss It has been difficult to ameliorate various diseases caused by reduced skin cell division function such as symptom, dandruff and itching.
[0004]
Therefore, the present inventor has created an environment similar to the skin cell interstitial fluid on the skin surface to activate the skin cells and improve various diseases caused by the decreased cell functions of the skin cells, and to maintain the electrolyte balance and osmotic pressure balance. By applying it, the inventors have invented aqueous skin and hair cosmetics that can promote normalization of damaged cells from the surface of the skin (Japanese Patent No. 1597430).
[0005]
In the case of this aqueous skin and hair cosmetic, in the case of spots and red face, the subcutaneous cells are stimulated and divided, leading to healing. The effect of stimulating hair and promoting hair growth and deodorizing action was observed. In other words, the aqueous skin and hair cosmetics have obtained efficacy results such as a cure rate for alopecia of 83%, a cure rate for pigmentation of 95%, and a cure rate of red face of 53%.
[0006]
However, these effects are recognized mainly for skin and hair, and the present inventors activate mucosal cells without side effects such as activation of skin cells and the like. If possible, we focused on the possibility that the effect could also be applied to diseases such as stomatitis due to oral mucosal disease and hay fever due to damage to the nasal mucosa.
[0007]
Therefore, the present inventor further has no fear of side effects even when used as an external preparation for oral cavity or nasal mucosa, and can be applied to various diseases in a wider range of cells such as stomatitis and hay fever. Has invented an external preparation for promoting cell activity (Japanese Patent No. 2681527). This external preparation for promoting cell activity is obtained by adding polysaccharides such as dextran, glucose, mutan, lentinan and the like. With this cell activity promoting external preparation, excellent results have been obtained, such as a cure rate for stomatitis of 100% and a cure rate for hay fever of 100%.
[0008]
[Problems to be solved by the invention]
However, the cure rate for hay fever shown in the above-mentioned external preparation for promoting cell activity was shown at the time when the number of subjects was 40, and as the number of patients with hay fever increased rapidly thereafter, pollen The cure rate of the disease tended to decrease gradually. In other words, the effectiveness rate, which showed 100% in hay fever in the previous efficacy test (Heisei 2), is an effective rate so that it is inversely proportional to the explosive increase in the incidence rate after 10 years. It has been found that is falling rapidly. In the first place, the cause of the development of hay fever has not yet been clarified, but it is thought that personal factors have some influence on the cellular level of the oral cavity and nasal mucosa to induce the onset. Therefore, by improving the immunity and healing power of the oral cavity, nasal mucosa, etc. and keeping the cellular tissue in a healthy state, it becomes possible to prevent adverse effects due to individual factors and suppress the onset of rapidly increasing hay fever. At the same time, it is considered that a healing effect is also produced.
[0009]
Therefore, the present invention further improves the immunity and healing power of cell tissues such as the oral cavity and the nasal mucosa by adding further improvements to the cell activity promoting external preparation previously invented, and there is no risk of side effects. It is an object of the present invention to provide an external preparation for promoting cell activity that can be applied not only to stomatitis but also to various diseases in a wide range of cells such as skin and scalp.
[0010]
[Means for Solving the Problems]
In order to achieve the above-mentioned object, the first means of the present invention is as follows: in an aqueous solution in which a polysaccharide is dissolved , dextran 18%, glucose 10%, cyclodextrin 2%, trehalose 3%, pullulan 7 in the total weight ratio. %, Lentinan 7%, laminaran 2%, krestin 1%, pectin 3%, xyloglucan 1%, sodium chloride 0.9%, calcium chloride 0.3%, potassium chloride 0.3%, purified water 44.5% This is because all the components were added.
[0011]
Causes of various symptoms such as inflammation, pigmentation, and alopecia that are lesions in human skin are related to various factors such as ultraviolet rays and chemical substances, and their changes at the cellular level are limited. The root of this is a disorder of the mitochondrial membrane and cell membrane, one of the organelles. In other words, damage to the mitochondrial membrane results in inhibition of intracellular respiration, thereby reducing the production of ATP (adenosine triphosphate), which is the source of cellular activity. Such a deficiency in ATP reduces the function of active transport of the cell membrane, leading to a decrease in the ability to transport substances between cells and interstitial fluid. This causes a vicious circle in which intracellular deprivation substances such as glucose are deficient, leading to a decrease in the acidity of ATP.
[0012]
There are a variety of causes that cause changes at the cellular level as described above. In particular, in cells such as the oral cavity and nasal mucosa, the cells in the diseased part are removed by raising the cell interstitial fluid by osmotic pressure action. Can be activated. Furthermore, it is considered that by adding xyloglucan, lamiranan and krestin, the immunity and healing power of cell tissues such as the oral cavity and nasal mucosa can be enhanced.
[0013]
DETAILED DESCRIPTION OF THE INVENTION
The basic formulation of the present invention is to add each component of xyloglucan, lamiranan, and krestin to an aqueous solution in which a polysaccharide is dissolved.
[0014]
Xyloglucan is a constituent sugar chain that exists universally on the wall (primary wall) of plant cells that are elongated and enlarged. Plant species specificity arises from the binding of galactose or fucosyl-galactose to xylose residues. Lectins can bind to these galactose and fucose residues, but the functions of these branched sugar chains are not known. Plant cell growth is caused by a water absorption phenomenon derived from the osmotic pressure of the cell, and water absorption is caused by a decrease in wall pressure due to loosening of the cell wall. This loosening of the cell wall has not yet been elucidated, but cell elongation is always accompanied by degradation and solubilization of xyloglucan, and is attracting attention as one of the polysaccharides that control the physiological activity of cells.
[0015]
Ramilanan is one of the carbohydrates and is classified as a β-glucan lamiranan. It is contained in seaweeds such as shiitake mushrooms and kelp and has the effect of enhancing immunity. It is known that it is difficult to absorb by itself and should be taken with protein.
[0016]
Krestin is used as an immunotherapeutic drug that enhances the expression of HLA class I antigens in human cancer cells, and is extracted from chopped mycelium. This krestin has been shown to have an immunotherapeutic effect on neoplastic diseases such as gastric cancer, colorectal cancer, and small cell lung cancer.
[0017]
As a result of researching ingredients suitable for external preparations from among many polysaccharides, the inventor has combined these xyloglucans, lamiranans, and krestins to immunize and heal cellular tissues such as the oral cavity and nasal mucosa. This is a preparation for external use that increases strength.
[0018]
In an aqueous solution in which these polysaccharides are dissolved, each component of pectin, dextran, glucose, lentinan, and trehalose is previously contained in a total weight ratio.
[0019]
Pectin functions to connect plant cells by binding to other components such as cellulose as a component of plant cell walls. It is a component having a gelling action and is suitable as an additive for the external preparation of the present invention.
[0020]
Moreover, sodium chloride, calcium chloride, and potassium chloride are added to the aqueous solution in which the polysaccharide is dissolved. The amount of sodium chloride is 0.9% in terms of the total weight ratio so that the osmotic pressure balance and the electrolyte balance on the skin, that is, the skin cells can be activated, and similarly 0.3% in calcium chloride and potassium chloride. % Of each component is dissolved in the aqueous phase component.
[0021]
【Example】
Next, the preparation for external use of the present invention will be specifically described with reference to formulation examples and pharmacological test examples.
[0022]
-Prescription example-
Dextran 18
Glucose 10
Cyclodextrin 2
Trehalose 3
Pullulan 7
Lentinan 7
Lamina Run 2
Krestin 1
Pectin 3
Xyloglucan 1
Sodium chloride 0.9
Calcium chloride 0.3
Potassium chloride 0.3
Purified water 44.5
Total weight ratio (%) 100
[0023]
The water phase component (purified water) is a non-oil produced only with pure water, and does not contain any water-soluble petroleum-based surfactants used at the time of producing ordinary external preparations such as cosmetics. And when mixing each of these components and an aqueous phase component, in order to complete melt | dissolution of each component, it implements at the temperature of 50-100 degreeC.
[0024]
Next, Table 1 shows the effects of Formulation Example 1.
[0025]
[Table 1]
[0026]
Table 1 shows the results of the pharmacological test of Formulation Example 1. The effectiveness at this time is the total score for each person, with 0 points indicating no change, 1 point indicating a change in healing, and 2 points indicating a confirmed effect due to the use of the external preparation of the present invention. And calculated by the following formula. In addition, in this test, in order to confirm the curative effect of hay fever in particular, the effective rate was calculated for 100 patients with disease.
[0027]
[Expression 1]
[0028]
As a result, an effective rate of 98% was obtained even for 100 people with hay fever. The effectiveness rate, which showed 100% in hay fever in the previous study (Heisei 2), has increased sharply so that it is inversely proportional to the explosive increase in the incidence rate after 10 years. Although it was decreasing, it can be said that it is a remarkable effect that the effective rate of 98% can be maintained by the present invention. In addition, only one of the 600 cases has no side effects, and is extremely effective for diseases that are difficult to improve, such as androgenetic alopecia, acne, athlete's foot, and seborrheic dermatitis.
[0029]
【The invention's effect】
According to the present invention, dextran 18%, glucose 10%, cyclodextrin 2%, trehalose 3%, pullulan 7%, lentinan 7%, laminaran 2%, krestin 1%, pectin 3%, xyloglucan By adding each component of 1%, sodium chloride 0.9%, calcium chloride 0.3%, potassium chloride 0.3%, purified water 44.5% to the aqueous phase component, It becomes possible to enhance the immunity and healing power of the cell tissue, and an effective healing effect can be obtained even in diseases in which individual factors such as pollinosis act.
[0030]
In addition, it can create an environment similar to that of skin cell interstitial fluid while enhancing the immunity and healing power of cellular tissues, so that inhibition of intracellular respiration caused by mitochondrial membrane damage and ATP as the source of cellular activity (Adenosine triphosphate) production can be prevented, electrolyte balance and osmotic pressure balance can be maintained, and normalization of damaged cells can be promoted from the surface layer of skin cells and mucosal cells. The present invention is extremely effective even for diseases that are difficult to improve, such as type alopecia, acne, athlete's foot, and seborrheic dermatitis, and the significance of the present invention is extremely great and greatly contributes to mankind.
Claims (1)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002113217A JP3885204B2 (en) | 2002-04-16 | 2002-04-16 | External agent for promoting cell activity |
TW092103549A TWI254639B (en) | 2002-04-16 | 2003-02-20 | External preparations for enhancing cell activity |
AU2003213370A AU2003213370A1 (en) | 2002-04-16 | 2003-03-05 | External preparations for enhancing cell activity |
PCT/JP2003/002536 WO2003086421A1 (en) | 2002-04-16 | 2003-03-05 | External preparations for enhancing cell activity |
CNB031088236A CN1240392C (en) | 2002-04-16 | 2003-03-26 | Agent for promoting cell activation for external use |
HK04102877A HK1060048A1 (en) | 2002-04-16 | 2004-04-23 | Agent for external application for enhancing cell activation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002113217A JP3885204B2 (en) | 2002-04-16 | 2002-04-16 | External agent for promoting cell activity |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005289815A JP2005289815A (en) | 2005-10-20 |
JP3885204B2 true JP3885204B2 (en) | 2007-02-21 |
Family
ID=29243346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002113217A Expired - Lifetime JP3885204B2 (en) | 2002-04-16 | 2002-04-16 | External agent for promoting cell activity |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP3885204B2 (en) |
CN (1) | CN1240392C (en) |
AU (1) | AU2003213370A1 (en) |
HK (1) | HK1060048A1 (en) |
TW (1) | TWI254639B (en) |
WO (1) | WO2003086421A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005053841A (en) * | 2003-08-05 | 2005-03-03 | Kyouto Biomedical Science:Kk | Skin care preparation for external use |
CN1285382C (en) * | 2004-12-20 | 2006-11-22 | 凌沛学 | Transmission system of drug for nasal cavity of containing trehalose and byaluronic acid, and preparation method |
DE102007052380A1 (en) * | 2007-10-31 | 2009-05-07 | Bitop Ag | Osmolyte-containing preparations for use in dry mucous membranes |
JP5620168B2 (en) * | 2010-06-30 | 2014-11-05 | Dsp五協フード&ケミカル株式会社 | Xyloglucan-cation complex and stabilized composition containing the same |
CN103239571B (en) * | 2013-05-26 | 2014-09-03 | 广州市云桥生物科技有限公司 | Chinese medicine effective part composition for treating alopecia areata and preparation method thereof |
JP6313118B2 (en) * | 2014-05-16 | 2018-04-18 | 株式会社Cac | IgE inhibitor |
RU2709464C2 (en) * | 2015-09-29 | 2019-12-18 | Кимберли-Кларк Ворлдвайд, Инк. | Synergistic composition for maintaining healthy microflora balance |
US12029748B2 (en) | 2017-02-28 | 2024-07-09 | Kimberly-Clark Worldwide, Inc. | Synergistic composition for maintenance of healthy balance of microflora |
FR3064473B1 (en) * | 2017-04-03 | 2021-02-12 | Basf Beauty Care Solutions France Sas | PROTECTIVE INGREDIENT OF THE BALANCE OF SKIN AND / OR MUCOSAL MICROBIAL FLORA |
BE1027425B1 (en) * | 2019-07-01 | 2021-02-08 | Aquilon Pharmaceuticals | INHALABLE COMPOSITION INCLUDING CYCLODEXTRIN FOR USE IN THE TREATMENT OF NASAL INFLAMMATIONS |
DE212021000176U1 (en) * | 2021-10-16 | 2022-01-04 | Nantong Jujiu New Material Science and Technology Co., Ltd. | Peripheral blood mononuclear cell culture dish coated with Yunzhi polysaccharide |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03204804A (en) * | 1989-12-28 | 1991-09-06 | Mitsui Toatsu Chem Inc | Skin cosmetic |
JP2681527B2 (en) * | 1990-02-15 | 1997-11-26 | ジャパンファインケミカル株式会社 | Topical for promoting cell activity |
DE19710368A1 (en) * | 1997-03-13 | 1998-09-17 | Henkel Kgaa | Use of water-soluble beta-glucans as active ingredients for the production of therapeutic agents for skin treatment |
JP2002275046A (en) * | 2001-03-23 | 2002-09-25 | Kanebo Ltd | Agent for enhancing barrier against penetration through epidermis, and skin care composition |
-
2002
- 2002-04-16 JP JP2002113217A patent/JP3885204B2/en not_active Expired - Lifetime
-
2003
- 2003-02-20 TW TW092103549A patent/TWI254639B/en not_active IP Right Cessation
- 2003-03-05 AU AU2003213370A patent/AU2003213370A1/en not_active Abandoned
- 2003-03-05 WO PCT/JP2003/002536 patent/WO2003086421A1/en active Application Filing
- 2003-03-26 CN CNB031088236A patent/CN1240392C/en not_active Expired - Fee Related
-
2004
- 2004-04-23 HK HK04102877A patent/HK1060048A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TW200407154A (en) | 2004-05-16 |
AU2003213370A1 (en) | 2003-10-27 |
HK1060048A1 (en) | 2004-07-30 |
JP2005289815A (en) | 2005-10-20 |
CN1451389A (en) | 2003-10-29 |
TWI254639B (en) | 2006-05-11 |
WO2003086421A1 (en) | 2003-10-23 |
CN1240392C (en) | 2006-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2681527B2 (en) | Topical for promoting cell activity | |
US9629856B2 (en) | Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds | |
JP3885204B2 (en) | External agent for promoting cell activity | |
RU2491928C1 (en) | Artificial saliva containing amino acid and using basic amino acid for treating dry mouth | |
JPH05503280A (en) | Topical preparations for the treatment of conditions of teeth and their supporting tissues | |
FR2464068A1 (en) | COMPOSITIONS BASED ON DIMETHYLSULFOXIDE AND THEIR APPLICATIONS, IN PARTICULAR THERAPEUTICS | |
Neena et al. | An ancient herb aloevera in dentistry: A review | |
TWI278318B (en) | External preparations for treating dermatitis | |
AU705996B2 (en) | External therapeutic composition for dermatitis | |
JP3890563B2 (en) | Permanent wave agent | |
ES2494928T3 (en) | Composition comprising mucilaginous polysaccharides derived from Aloe barbadensis combined with liposomes, method for obtaining them and their use as sunscreen, an anti-acne agent, an epidermal regenerator and a moisturizer | |
JPH0212443B2 (en) | ||
JP3503880B2 (en) | Oral composition | |
CN113876788A (en) | Salidroside hydrogel preparation and preparation method and application thereof | |
KR0141930B1 (en) | Dermatological composition based on an aqueous phase | |
JP2766811B2 (en) | Aqueous skin external preparation | |
JPH10287550A (en) | Preparation for external use for skin | |
JP2723473B2 (en) | Uses of sulfated saccharides | |
KR20120001872A (en) | Cosmetic composition containing spring water and pueraria lobata root extract for sensitive skin and its producing method | |
RU2092156C1 (en) | Solution for skin repair stimulation | |
EP1296667B1 (en) | Compounds for preventing and/or treating urticaria | |
US7018661B2 (en) | Aluminum-zirconium compound-based treatment for herpes simplex virus lesions | |
JPS6023325A (en) | Ointment for dermatosis | |
EP3941484A1 (en) | Chitosan nitrate for use as a nitric oxide donor (no donor) | |
KR20090099112A (en) | Functional toothpaste including nano silver |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060502 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060711 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060810 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060919 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061024 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20061110 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 3885204 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101201 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111201 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121201 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131201 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |